ライフサイエンスコーパス: transdermal

1 N = 34) or testosterone (three doses of 10 g transdermal 1% testosterone gel over 48 hours, N = 41) t

2 randomly active treatment (n=34; 3 months of transdermal 17 beta-oestradiol 200 micrograms daily alon

3 Transdermal 17B-estradiol plus cyclic progestin was asso

4 al (N=12) received open-label treatment with transdermal 17beta-estradiol (100 micro g/day) for 4 wee

5 ated equine estrogens (o-CEE), 0.45 mg/d, or transdermal 17beta-estradiol (t-E2), 50 mcg/d, each with

6 n difference, -16.8; 95% CI, -23.4 to -10.2; transdermal 17beta-estradiol, 6 trials: pooled weighted

7 xposures, it is important to consider direct transdermal absorption from air.

8 Transdermal administration by iontophoresis (enhanced tr

9 Moreover, transdermal administration of GTN attenuated tumor growt

10 effectively prevented by i.v. injection and transdermal administration of Hph-1-ctCTLA-4.

11 <0.05) improvement in bioavailability, after transdermal administration of nanotransfersomal ATV gel

12 e studied the effect of 3 days of continuous transdermal administration of nitroglycerin (NTG) (10 mg

13 Three days of continuous transdermal administration of NTG was accompanied by inc

14 ent study was undertaken to evaluate whether transdermal administration of the alpha2 adrenergic-rece

15 ormoxia and sympathetic inhibition (via 48 h transdermal administration of the centrally acting alpha

16 Finally, transdermal administration of the nitric oxide (NO) mime

17 n, thus supporting painless and non-invasive transdermal administration.

18 ess excellent physicochemical properties for transdermal administration.

19 ntial application of this device in wearable transdermal alcohol measurements.

20 tionally being required to wear a continuous transdermal alcohol monitoring anklet.

21 tudy provided experience in using continuous transdermal alcohol monitors in an experimental context,

22 o design a research project using continuous transdermal alcohol monitors with ex-offenders who recog

23 were administered to C57BL/6 female mice via transdermal alone and in combination with the oral route

24 round 1.5 times tumor suppression in case of transdermal and combination of routes at the end of 15th

25 Although recent advances in transdermal and oral delivery have been significant, bot

26 Here we report in vivo noninvasive transdermal and transcranial imaging of the structure an

27 ood pressure, as well as the nonoral routes (transdermal and vaginal).

28 Preoperative transdermal (and oral) clonidine administration resulted

29 significantly increased separately for oral, transdermal, and implanted oestrogen-only formulations (

30 These results demonstrate that systemic or transdermal application of a cell-permeable form of the

31 rs, as drug delivery systems for topical and transdermal applications.

32 work a novel self-powered microneedle-based transdermal biosensor for pain-free high-accuracy real-t

33 The proposed transdermal biosensor makes use of an array of silicon-d

34 The combined administration of oral and transdermal clonidine effectively attenuated the catecho

35 icipants were randomly assigned to receive a transdermal contraceptive patch (n = 812) vs an OC (n =

36 of siRNA may overcome certain limitations to transdermal delivery (specifically keratinocyte uptake)

37 um lauryl sulfate enhances the efficiency of transdermal delivery and delays the recovery of the barr

38 may serve as promising means for controlled transdermal delivery and targeted intradermal administra

39 ng with the development of novel vehicles of transdermal delivery and the use of anesthetics in combi

40 gement options included oral, parenteral and transdermal delivery forms of opioid analgesics; externa

41 Transdermal delivery is an advantageous method of drug a

42 and third-generation enhancement strategies, transdermal delivery is poised to significantly increase

43 carbonyl-5-fluorouracil, is known to enhance transdermal delivery of 5-fluorouracil, an important sys

44 ression in exploitation of MN for successful transdermal delivery of a much wider range of drugs.

45 show promise for the electrically controlled transdermal delivery of biomacromolecules in a simple, o

46 These findings suggest that transdermal delivery of DFO provides a targeted means to

47 ulcer model in diabetic mice, we found that transdermal delivery of DFO significantly improved wound

48 sential for chemical exposure assessment and transdermal delivery of drugs.

49 tablished as one of the methods of enhancing transdermal delivery of drugs.

50 emonstrate for the first time the concurrent transdermal delivery of erlotinib and IL36alpha siRNA as

51 The enhanced co-transdermal delivery of erlotinib and IL36alpha siRNA by

52 Transdermal delivery of hydrophilic drugs is challenging

53 demonstrated improved immune responses after transdermal delivery of inactivated influenza virus with

54 Microneedles (MNs) allow transdermal delivery of otherwise skin-impermeable drugs

55 e demonstrated that electroporation-mediated transdermal delivery of peptides, polysaccharides, oligo

56 bioavailability and poor skin permeability, transdermal delivery of protein therapeutics poses a sig

57 effect of MN heigth and MN density upon the transdermal delivery of small hydrophilic compounds (the

58 m of this investigation was to visualize the transdermal delivery of sulforhodamine B (SRB), a fluore

59 les to promote skin rejuvenation or increase transdermal delivery of topical medications.

60 The benefits of transdermal delivery over the oral route to combat such

61 Indeed in in vitro transdermal delivery studies, approximately 33mg (90%) o

62 expectedly, prophylactic application of this transdermal delivery system also prevented diabetic ulce

63 ide using a dissolvable microstructure-based transdermal delivery system.

64 nicotine BA from two, matrix-type, nicotine transdermal delivery systems (TDS).

65 for assuring the quality and performance of transdermal delivery systems and topical patches (collec

66 First-generation transdermal delivery systems have continued their steady

67 e investigations revealed that the extent of transdermal delivery was dependent upon the design of th

68 may broaden the range of drugs suitable for transdermal delivery, as well as enabling the rate of de

69 During transdermal delivery, the first viable cells exposed to

70 s potential in the MN mediated iontophoretic transdermal delivery.

71 rm of an active therapeutic agent to enhance transdermal delivery.

72 pid to disrupt the skin barrier for enhanced transdermal delivery.

73 of CPEs that can aid the design of optimized transdermal, dermatological, and cosmetic formulations i

74 cers (CPEs) are present in a large number of transdermal, dermatological, and cosmetic products to ai

75 nic detection of ingested medicines based on transdermal detection of nontoxic long-wavelength fluoro

76 s administered alternatively, beginning with transdermal dose.

77 of combination of routes, mice were given 5 transdermal doses and 5 oral doses administered alternat

78 ne to rationally design better enhancers for transdermal drug and vaccine delivery by electroporation

79 ly shown to enable skin permeabilisation for transdermal drug and vaccine delivery, by sequentially a

80 provide insight into the development of new transdermal drug carriers to treat a variety of skin dis

81 By any measure, transdermal drug delivery (TDD) is a successful controll

82 density led to an increase in the extent of transdermal drug delivery achieved 6h after MN applicati

83 imally-invasive fashion and achieve enhanced transdermal drug delivery and "targeted" intradermal vac

84 ployed as the active element of a switchable transdermal drug delivery device that can facilitate mor

85 highlighted the importance of MN design for transdermal drug delivery enhancement, to date, there ha

86 The widespread adoption of transdermal drug delivery has been limited by the barrie

87 Transdermal drug delivery has made an important contribu

88 Although transdermal drug delivery has many potential advantages,

89 Transdermal drug delivery is limited by the barrier prop

90 Although transdermal drug delivery is more attractive than inject

91 icant difference in absorption of drugs from transdermal drug delivery is observed in different age g

92 To improve HIF-1alpha activity we designed a transdermal drug delivery system (TDDS) containing the F

93 C) for drug-in-adhesive (DIA) type estradiol transdermal drug delivery systems (TDDS).

94 ology lends itself both to the prediction of transdermal drug delivery, and the feasibility of this r

95 etration enhancers are often used to enhance transdermal drug delivery.

96 um height resulted in the greatest extent of transdermal drug delivery.

97 rs playing a significant role in US-mediated transdermal drug delivery.

98 iers is presented, with special attention to transdermal drug delivery.

99 ultrasound presents an attractive method for transdermal drug delivery.

100 ression with a chromogenic reporter, mapping transdermal drug distributions without histological sect

101 Transdermal E(2) had no effect on CRP or IGF-1 levels.

102 Neither transdermal E(2) nor oral CEE had any effects on the pla

103 We investigated the effects of this transdermal electrical neurosignaling (TEN) method on sy

104 Intravesical or transdermal electrical stimulation, sacral nerve stimula

105 enhancers (CPEs), especially surfactants, in transdermal enhancement has been investigated extensivel

106 Because the effects of transdermal ERT are larger than those of oral ERT, the r

107 n normotensive postmenopausal women, chronic transdermal ERT decreases SND without augmenting arteria

108 After 8 weeks of transdermal ERT, the basal rate of SND decreased by 30%

109 5 mg per day) in 30 postmenopausal women and transdermal estradiol (0.1 mg per day) in 20 postmenopau

110 fter 3 weeks of open-label administration of transdermal estradiol (100 microg/d), participants were

111 ty were measured before and after 8 weeks of transdermal estradiol (200 microgram/d), oral conjugated

112 factor-alpha before and after eight weeks of transdermal estradiol (E(2)) (100 microg/day), oral conj

113 th, 211 women randomized to receive 50 mug/d transdermal estradiol (t-E2) plus 200 mg/d m-P for the f

114 ily oral conjugated equine estrogen (CEE) or transdermal estradiol alters hemostatic factors in postm

115 Transdermal estradiol caused no significant changes in P

116 ly different from the change observed in the transdermal estradiol group (p < 0.05).

117 Transdermal estradiol had no significant effect on lipid

118 Transdermal estradiol has been associated with virtually

119 Transdermal estradiol replacement is an effective treatm

120 itor-1 antigen declined in both oral CEE and transdermal estradiol users, but did not achieve statist

121 o receive daily oral CEE, 0.625 mg (n = 21); transdermal estradiol, 0.1 mg/day (n = 7); or oral place

122 taneously 3 times/wk) + sex steroids (women: transdermal estradiol, 100 micro g/d, plus oral medroxyp

123 d, crossover trial to evaluate the effect of transdermal estradiol, with and without vaginal microniz

124 as known thromboembolic risk, and lower-dose transdermal estrogen formulations are preferred over hig

125 ting of 103 women who were receiving oral or transdermal estrogen-replacement therapy (44 of whom wer

126 In postmenopausal women, oral but not transdermal ET increased CRP by a first-pass hepatic eff

127 When the device was fed with transdermal extracts, containing only 30 muM of glucose,

128 Therefore, we tested the effects of transdermal fentanyl (TDF) in patients with moderate-to-

129 uggest that patients are more satisfied with transdermal fentanyl compared with sustained-release ora

130 tion study in 62 adult cancer patients using transdermal fentanyl for persistent pain.

131 ency and reduced impact of side effects with transdermal fentanyl may be one reason cancer patients w

132 iven by 73.7% of patients (233/316) who used transdermal fentanyl PCA and 76.9% of patients (246/320)

133 Patients who received transdermal fentanyl were more satisfied overall with th

134 reasing patient compliance and expanding the transdermal field to a wider variety of clinical conditi

135 in vivo in a subcutaneous mouse model using transdermal fluorescent imaging to monitor degradation.

136 ology for evaluating transient, finite dose, transdermal flux data collected using traditional experi

137 d with glucose (180 Da) and inulin (5000 Da) transdermal flux experiments, which showed greater perme

138 ance, by one to two orders of magnitude, the transdermal flux.

139 tion of the time required to achieve maximal transdermal flux.

140 This investigation shows that the transdermal fluxes of highly lipophilic compounds can be

141 enteral polymeric microspheres/implants, and transdermal formulations), and briefly summarizes the kn

142 then randomly assigned to 14 weeks of daily transdermal gel that contained 10-g testosterone for 70

143 ial, the authors administered a testosterone transdermal gel to men aged 30-65 who had refractory dep

144 luorescence affinity hollow fiber sensor for transdermal glucose monitoring is demonstrated.

145 of these aggregates for use in physiological transdermal glucose monitoring, either for implantable s

146 Crucially, oral but not transdermal hormone-replacement therapy increases activa

147 benefits and harms of systemic (ie, oral or transdermal) hormone therapy for the prevention of chron

148 nogen, factor VII, and PAI (less change with transdermal HRT) and antithrombin III.

149 We found that transdermal iontophoresis of protons consistently caused

150 gue-Dawley rats to assess the feasibility of transdermal iontophoretic delivery in vivo, of a lipophi

151 tecting group that can be easily removed via transdermal light exposure to render the peptide fully a

152 ti-OVA IgG antibody levels compared to other transdermal methods.

153 This self-adherent transdermal MN platform can be applied to a variety of p

154 es and blood, facilitating their use for the transdermal monitoring of cyanide for mammalian safeguar

155 We engineered a transdermal neuromodulation approach that targets periph

156 at were identical, except that smokers had a transdermal nicotine (21 mg) or placebo patch placed bef

157 re randomly assigned to daily treatment with transdermal nicotine (n = 31) at the highest tolerated d

158 Transdermal nicotine administered at the highest tolerat

159 on specialists were modeled with and without transdermal nicotine and nicotine gum.

160 Abstinence rates for the transdermal nicotine and nicotine nasal spray groups wer

161 However, the efficacy of transdermal nicotine as an aid to smoking cessation in s

162 The transdermal nicotine delivery device was able to success

163 a nicotine formulation to obtain switchable transdermal nicotine delivery rates on human skin (in vi

164 tor for acute cardiovascular events, whereas transdermal nicotine does not appear to do so.

165 Transdermal nicotine does not cause a significant increa

166 Transdermal nicotine for 24 weeks increased biochemicall

167 ng smokers of European ancestry treated with transdermal nicotine in two independent cohorts.

168 Transdermal nicotine may help control clinical manifesta

169 igarette smoking than the slower delivery by transdermal nicotine or nicotine gum.

170 ardiovascular disease to a 10-week course of transdermal nicotine or placebo as an aid to smoking ces

171 fferent days under each condition, wearing a transdermal nicotine or placebo patch.

172 were scanned under each condition wearing a transdermal nicotine or placebo patch.

173 All subjects received 8 weeks of a transdermal nicotine patch, five group counseling sessio

174 the pharmaceutical company could market its transdermal nicotine patch.

175 ls found in human smokers or in users of the transdermal nicotine patch.

176 ls found in human smokers or in users of the transdermal nicotine patch.

177 to those found in smokers or in users of the transdermal nicotine patch.

178 s, for the NHS, of allowing GPs to prescribe transdermal nicotine patches for up to 12 weeks.

179 If GPs were allowed to prescribe transdermal nicotine patches on the NHS, for up to 12 we

180 Attention task performance was improved by transdermal nicotine relative to placebo, with intermedi

181 Transdermal nicotine replacement improved task performan

182 Transdermal nicotine therapy is widely used to aid smoki

183 nence after a lapse compared with 8 weeks of transdermal nicotine therapy.

184 The failure of transdermal nicotine to alter reward-related functional

185 rformed in 9 nonsmokers and 9 smokers during transdermal nicotine treatment (14 mg).

186 white achieved higher abstinence rates with transdermal nicotine, whereas smokers who were highly de

187 eeks of therapy with nicotine nasal spray or transdermal nicotine.

188 died the effects of high-dose (50 to 100 mg) transdermal nitroglycerin (NTG) and placebo given daily

189 long-term (6-month) efficacy of intermittent transdermal nitroglycerin (NTG) patches on LV remodeling

190 ught to evaluate the effects of intermittent transdermal nitroglycerin (TD-NTG) on the occurrence of

191 Application of transdermal nitroglycerin patches or treatment with L-ar

192 these malaria-specific nanobubbles provided transdermal noninvasive and rapid detection of a malaria

193 Neither transdermal nor oral ERT had any effects on baroreflex s

194 Transdermal NTG (0.2 to 0.4 mg/h) significantly reduced

195 ced by IV NTG, demonstrating the efficacy of transdermal NTG as an alternative form of NTG delivery f

196 Transdermal NTG patches elicited a late PC effect that w

197 Transdermal NTG patches prevent LV dilation in patients

198 After 1 month of transdermal oestradiol replacement in these women, the n

199 This study has shown that transdermal oestrogen is an effective treatment for post

200 l tablets, buccal tablets, sublingual spray, transdermal ointment, and transdermal patch, as well as

201 nonobstetric sample; used oral, topical, or transdermal opioids; and focused on treatment for chroni

202 eater or lesser abstinence rates with either transdermal or nasal spray nicotine.

203 Transdermal or vaginal estrogen resulted in inconsistent

204 Transdermal OVA doses of up to 1mug were achieved in a s

205 d in 10 weeks of treatment with the nicotine transdermal patch (21 mg/day) and 10 weekly group therap

206 on to sustained release oral medication, the transdermal patch and the intravaginal route are startin

207 rder who were also treated with the nicotine transdermal patch and with either atypical or typical an

208 1) smoking cessation rates with the nicotine transdermal patch are modest in schizophrenia, 2) specia

209 nicotine (TNP; n=37) or placebo (PBO; n=43) transdermal patch following overnight abstinence complet

210 ical agents in combination with the nicotine transdermal patch for smoking cessation in schizophrenia

211 randomized, crossover trial that compared a transdermal patch of ABT-418 (75 mg/day) to placebo in a

212 randomization to 5 mg testosterone daily by transdermal patch or matching placebo for 12 weeks, in a

213 st that can be administered once daily or by transdermal patch seems to be a reasonable option to con

214 Recent additions include a contraceptive transdermal patch, a hormone-releasing intravaginal ring

215 replacement group received a 21-mg nicotine transdermal patch, and those in the placebo group were t

216 sublingual spray, transdermal ointment, and transdermal patch, as well as intravenous formulations.

217 raceptive methods (oral contraceptive pills, transdermal patch, contraceptive vaginal ring, and depot

218 tic agents, in combination with the nicotine transdermal patch, significantly enhanced the rate of sm

219 r systemic delivery of macromolecules from a transdermal patch.

220 st that can be administered once daily or by transdermal patch.

221 A shorter acting contraceptive option is the transdermal patch.

222 delivery that are inspired by the design of transdermal patches and demonstrate their capabilities i

223 ording to DSM-IV, were randomized to receive transdermal patches of 17beta-estradiol (100 microgram)

224 been fabricated and envisioned for use with transdermal patches or infusion pumps to achieve painles

225 up to 8-weeks treatment with NRT (15 mg/16 h transdermal patches) or identically packaged and visuall

226 stems that make use of micro/nano-particles, transdermal patches, inhalers, drug reservoir implants a

227 For transdermal patches, the corresponding relative risks we

228 skin by using a fluorescent dye to probe the transdermal pathways of the enhancer.

229 complex structure of the stratum corneum on transdermal penetration is not yet fully described by ex

230 Visualization of transdermal permeant pathways is necessary to substantia

231 The effect of vehicle mixtures on transdermal permeation has been studied using transient

232 teral transport on skin, combined with a low transdermal permeation rate, may thus be seen to be a ke

233 Transdermal photo-cross-linking of acrylated biopolymers

234 lish the validity of these modeling studies, transdermal photopolymerization first was applied to tis

235 his phenomenon and test the applicability of transdermal photopolymerization for drug release devices

236 With further study, transdermal photpolymerization potentially could be used

237 were assigned to receive either double-blind transdermal placebo or maximally tolerated TD-NTG for 2

238 l to the operating room) or matched oral and transdermal placebo.

239 Modeling predicted the feasibility of transdermal polymerization with only 2 min of light expo

240 neous electroreceptors detect changes in the transdermal potential (TDP) as the fish interact with co

241 quency, weak electric field and perceive the transdermal potential modulations caused by a nearby tar

242 ht use the spectral content of the perceived transdermal potential modulations to classify the living

243 Over the last 30+ years, a steady flux of transdermal products have received regulatory approval a

244 Here, we present a new approach for transdermal protein delivery using bullet-shaped double-

245 in three phases: pretreatment (Phase A1), on transdermal rotigotine for 7-11 days (Phase B) and post-

246 ministration of NTG via either the IV or the transdermal route elicits a robust protective effect aga

247 rogen-replacement therapy, primarily via the transdermal route, increases BMD in adolescents, althoug

248 biologically active macromolecules, via the transdermal route.

249 m encapsulating ATV for its delivery via the transdermal route.

250 pproaches (e.g., oral, nasal, pulmonary, and transdermal routes) for protein delivery.

251 A transdermal SARM has a potential to have therapeutic ben

252 us tear production was inhibited by applying transdermal scopolamine (scop) patches to the depilated

253 benefit from long-acting antiemetics such as transdermal scopolamine, aprepitant, and/or palonosetron

254 Transdermal selegiline (20 mg applied once daily by mean

255 e disorder were randomly assigned to receive transdermal selegiline (20 mg applied once daily by mean

256 hors investigated the efficacy and safety of transdermal selegiline in adult outpatients with major d

257 ty for high doses of oral selegiline and for transdermal selegiline suggesting that when plasma level

258 erved after 6 weeks in patients treated with transdermal selegiline than in those given placebo accor

259 Mice were rendered hazelnut allergic by a transdermal sensitization/oral elicitation protocol.

260 to improve the stability and reliability of transdermal sensors, due to the reduction of the detrime

261 g deeply penetrating near-infrared light for transdermal stiffness modulation, enabling external cont

262 f insulin, including oral, nasal, pulmonary, transdermal, subcutaneous and closed-loop insulin delive

263 y (1950-1980) focused on developing oral and transdermal sustained release systems and establishing c

264 ) and in 3 subjects receiving the selegiline transdermal system (Emsam patch, 6 mg/day) using positro

265 ion over 10 minutes) by a patient-controlled transdermal system (n = 316).

266 While different technical aspects of transdermal system development have been discussed at va

267 he fentanyl hydrochloride patient-controlled transdermal system eliminates the need for venous access

268 An investigational PCA transdermal system using iontophoresis to deliver fentan

269 , which were more common with the selegiline transdermal system.

270 (ii) nanoparticle-based cancer drugs, (iii) transdermal systems, (iv) oral drug delivery systems, (v

271 ach for the development and manufacturing of transdermal systems.

272 Transdermal (TD) delivery provides an excellent alternat

273 blunting the clinical utility of this unique transdermal technique.

274 Transdermal testosterone alone has not been shown to imp

275 ave undergone oophorectomy and hysterectomy, transdermal testosterone improves sexual function and ps

276 We evaluated the effects of transdermal testosterone in women who had impaired sexua

277 p < 0.02) with use of oral estrogen (but not transdermal) therapy compared with women not receiving t

278 We demonstrate that non-invasive, transdermal time-regulated activation of cell-adhesive R

279 Ultrasound-enhanced transdermal transport is mediated by inertial cavitation

280 s a particularly important role in enhancing transdermal transport of macromolecules, thereby offerin

281 ral phospholipids, were found to enhance the transdermal transport of molecules by electroporation.

282 uired to accurately determine the changes in transdermal transport properties incurred globally, over

283 captures the relative changes in the global transdermal transport properties of the hydrophobic prob

284 The oleic-acid-induced changes in the transdermal transport properties of the model hydrophobi

285 etically derived mathematical expressions of transdermal transport to quantitatively characterize the

286 tant insight into the mechanistic changes in transdermal transport underlying the visualized changes

287 t, improvements in enhancing the efficacy of transdermal ultrasound treatments have been limited.

288 We recently reported that transdermal uptake directly from air could be comparable

289 tly reported (Indoor Air 2012, 22, 356) that transdermal uptake directly from air could be comparable

290 Transdermal uptake directly from air is a potentially im

291 However, transdermal uptake rates from air have not been measured

292 This study investigated transdermal uptake, directly from air, of diethyl phthal

293 levels to be lower on average with oral and transdermal use of hormone therapy (25.0 vs. 33.5 ng/ml,

294 s indicated that nanocup-assisted ultrasound transdermal vaccination achieved significantly (p<0.05)

295 mes tumor suppression when administered with transdermal vaccine and around 9 times tumor suppression

296 The transdermal vaccine was delivered using a metallic micro

297 o-controlled study to compare the effects of transdermal versus oral ET on CRP and inflammatory cytok

298 e results obtained suggest that the proposed transdermal vesicular system can serve as a promising al

299 The transdermal vesicular system exhibited a significant dec